Modality
Cell Therapy
MOA
EZH2i
Target
WEE1
Pathway
Amyloid
ADPKD
Development Pipeline
Preclinical
Nov 2021
PreclinicalCurrent
NCT07555894
1,637 pts·ADPKD
2021-11→TBD·Completed
1,637 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07555894 | Preclinical | ADPKD | Completed | 1637 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 |